KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2025)

Rigel Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $395000.0 for Q4 2025.

  • For Q4 2025, Operating Leases changed N/A year-over-year to $395000.0; the TTM value through Dec 2025 reached $395000.0, changed N/A, while the annual FY2025 figure was $395000.0, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $395000.0 at Rigel Pharmaceuticals, down from $556000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $17.2 million in Q1 2021 and troughed at $100000.0 in Q1 2024.
  • A 5-year average of $2.7 million and a median of $759000.0 in 2021 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: crashed 96.07% in 2021 and later skyrocketed 764.0% in 2025.
  • Year by year, Operating Leases stood at $759000.0 in 2021, then rose by 28.06% to $972000.0 in 2022, then plummeted by 70.68% to $285000.0 in 2023, then crashed by 64.91% to $100000.0 in 2024, then skyrocketed by 295.0% to $395000.0 in 2025.
  • Business Quant data shows Operating Leases for RIGL at $395000.0 in Q4 2025, $556000.0 in Q3 2025, and $714000.0 in Q2 2025.